Builds new capillaries.
Nurtures your body.

Neovasculgen® delivers the VEGF gene to target tissues via a plasmid. This gene encourages cells to produce VEGF protein, promoting angiogenesis and improving local oxygenation.

VEGF gene therapy is used for PAD. However, its physiological effects also support wound healing, muscle oxygenation, neuroprotection, hair follicle blood supply, and tissue regeneration.

Clinical trials of Neovasculgen® reported no systemic side effects. Recorded side effects were limited to temporary pain and itching at the injection sites and potential allergic reactions. It has been in clinical use in Russia and Ukraine since 2012, with more than 20,000 patients treated. VEGF gene therapy remains experimental and is not approved by the FDA; effects are not guaranteed and individual results vary.

PAD patients experience increased pain-free walking distance, improved local blood supply, and a higher Ankle-Brachial Index (ABI), which indicates better blood circulation in the legs. The effects on improving endurance and hair condition in healthy adults are under investigation. Potential effects include increased strength, recovery rate, reduced pain, increased muscle mass, better blood supply, increased local oxygen concentration, increased ABI, and higher VO2max. For scalp treatment, potential effects include: slowing down or reversal of hair loss, increased follicle size, and density.

More than 20,000 patients have successfully received VEGF gene therapy.

The treatment is delivered locally via a set of intramuscular injections, at least ten per session. For hair rejuvenation, the injections resemble a PRP treatment (over 30 and up to 100 injections).

• PAD patients and patients with diminished blood supply to the legs (e.g., due to type 2 diabetes or sarcopenia);
• If you experience early symptoms of age-related deterioration of hair quality.
• If you are looking for ways to enhance the performance of key muscles to gain VO2max improvement, better results at weightlifting, or any physical activity connected to the treated muscle groups.
• Patients looking for locally improved rates of healing after surgery or an accident.

Most commonly pain at the injection site, caused by the additional components in the drug that help the plasmids enter the cells. Temporary itching and potential allergic reactions have also been recorded. The therapy has been used in more than 20,000 people with no serious side effects reported, though that clinical experience comes from outside FDA jurisdiction.

All gene therapies, including VEGF, are banned by WADA.

Studies in PAD patients showed the effect lasting at least 5 years: it was still present at the last assessment of the 5-year follow-up. That is the length of the study rather than the limit of the effect, and nothing beyond 5 years has been measured. We recommend reinjecting in 3 years to maintain the maximum effect.

VEGF protein predominantly remains localized because it strongly binds to the extracellular matrix and primarily influences the immediate surrounding cells, especially endothelial cells. Its rapid uptake by cells through receptors, combined with its short half-life (approximately 30 minutes), restricts it from circulating widely, keeping it concentrated near the area of production.

The localized nature of VEGF means the accurate measurement of its expression requires direct tissue biopsies from the specific region of interest. However, monitoring VEGF expression effectively over time or across multiple areas would demand multiple invasive procedures. Since repeated biopsies of healthy tissues raise ethical issues and patient discomfort, direct measurement through biopsies isn’t standard practice for healthy tissues.

Data from Neovasculgen plasmid studies confirm active VEGF expression, with in vitro results showing VEGF protein levels increasing significantly from baseline (~11–27 pg/ml) to approximately 151 pg/ml within 96 hours after transfection. Additionally, preclinical mouse studies using a hind-limb ischemia model demonstrated a substantial increase in blood flow restoration, achieving up to 80–90% recovery at 35 days post-treatment, highlighting effective, sustained VEGF expression and therapeutic benefit.

A single vial of Neovasculgen contains 1.2 mg of VEGF plasmid, which translates to 17.5 mcg/kg for an average adult.

In preclinical toxicity trials, rats and dogs were injected with doses up to 10,000 mcg/kg daily for 90 days. That’s roughly 12,500 times the dose of the 4-vial human protocol. No significant side effects or deaths were observed during those studies. The therapeutic index of the drug is 10,000 (according to the Hodge & Sterner scale). It’s important to note that the dose above 2 vials per session wasn’t investigated in humans.

Thus, it’s not clear that it’s possible to overdose on VEGF Plasmid. We, however, do not recommend exceeding the 4 vials per session (and 4 more vials 7–21 days apart).

For VEGF together with AAV-follistatin there is now preclinical data: in mice, giving the VEGF plasmid first and AAV-follistatin afterwards produced more muscle growth in the treated limb and roughly double the capillary counts of follistatin alone (Vakhrusheva, 2026, a preprint that has not been peer reviewed). That pairing is being tested in people in the CALM-AF-AI trial (NCT07443826). For combinations with stem cells or with other gene therapies there is still no such data. The final decision is made by the treating physician and the patient.

For muscle: VO2max before and 6 months after, results in running/cycling/walking or any relevant activity, recovery rates after exercise (subjective), and muscle circumference.

For PAD: pain-free walking distance, and all of the above.

For hair: photos from the same angle before and 6 months after; trichoscopy exam (follicle size and density at various sites) before and 6 months after.